Asymchem Announces Opening of new R&D site

Asymchem Announces Opening of new R&D site

by admin December 20, 2022 December 20, 2022 No comments
Asymchem

Asymchem Laboratories a leading CDMO serving the global pharmaceutical and biotech industry, announced their opening of a new site in Woburn, Massachusetts – Asymchem Boston, a wholly owned subsidiary of Asymchem Group, as an important step to expand Asymchem’s global footprint. The new Boston site is focused on providing early-stage R&D services including chemical process development, pre-formulation study and formulation development for small molecules, peptides, and oligonucleotides.

Asymchem Boston not only provides direct service to biotech clients, but also serves as a liaison between its China-based manufacture sites and the company’s partners. Though the site’s current focus is on small molecules, it will soon engage with more oligonucleotide and peptide work within the next year. From medicinal chemistry support to IND-enabling, the site will be equipped with the capacity to assist in early-stage process development for both drug substance and drug product.

“Asymchem has been working diligently in recent years to bring biotech clients an even more well-rounded CMC experience when managing early-stage projects. The company’s expansion to Boston has become an integral part of this journey to better serve Asymchem’s national and global partners.” said, Dr. Hao Hong, Chief Executive Officer of Asymchem Group.

Leave comments

Your email address will not be published.*

<br><br>You may use these <abbr title="HyperText Markup Language">HTML</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Supportscreen tag